Back to Journals » ImmunoTargets and Therapy » Volume 3

Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response

Authors Dejaegher J, Van Gool S, De Vleeschouwer S

Received 4 December 2013

Accepted for publication 22 January 2014

Published 13 March 2014 Volume 2014:3 Pages 55—66


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Joost Dejaegher,1 Stefaan Van Gool,2 Steven De Vleeschouwer1

1Department of Neurosciences, 2Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium

Abstract: Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain cancer. Since median overall survival with multimodal standard therapy is only 15 months, there is a clear need for additional effective and long-lasting treatments. Dendritic cell (DC) vaccination is an experimental immunotherapy being tested in several Phase I and Phase II clinical trials. In these trials, safety and feasibility have been proven, and promising clinical results have been reported. On the other hand, it is becoming clear that not every GBM patient will benefit from this highly personalized treatment. Defining the subgroup of patients likely to respond to DC vaccination will position this option correctly amongst other new GBM treatment modalities, and pave the way to incorporation in standard therapy. This review provides an overview of GBM treatment options and focuses on the currently known prognostic and predictive factors for response to DC vaccination. In this way, it will provide the clinician with the theoretical background to refer patients who might benefit from this treatment.

Keywords: immunotherapy, personalized medicine, brain tumor, stratification

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]